Edition:
United States

Nuvo Pharmaceuticals Inc (NRI.TO)

NRI.TO on Toronto Stock Exchange

4.16CAD
18 Oct 2017
Change (% chg)

-- (--)
Prev Close
$4.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,117
52-wk High
$7.02
52-wk Low
$3.76

Latest Key Developments (Source: Significant Developments)

Nuvo Pharmaceuticals secures credit facility from RBC
Thursday, 24 Aug 2017 07:30am EDT 

Aug 24 (Reuters) - Nuvo Pharmaceuticals Inc :Nuvo Pharmaceuticals secures credit facility from The Royal Bank of Canada.Has secured a $6.0 million operating revolving credit facility with Royal Bank of Canada (RBC)​.  Full Article

Nuvo Pharmac reports Q2 loss per share of C$0.02 from cont ops
Wednesday, 9 Aug 2017 05:00pm EDT 

Aug 10 (Reuters) - Nuvo Pharmaceuticals Inc :Nuvo Pharmaceuticals™ announces 2017 second quarter results.Q2 loss per share c$0.02 from continuing operations.Q2 revenue c$3.1 million versus c$8.1 million.Nuvo Pharmaceuticals Inc - at quarter end, ‍cash and short-term investments increased to $20.0 million with no debt​.Nuvo Pharmaceuticals Inc - ‍reallocation of resources included reduction in size of primary care sales force that markets pennsaid 2% to physicians​.Nuvo Pharmaceuticals - has not yet seen negative impact from sales force reduction that might impact typical commercial bottle ordering patterns​.Nuvo Pharmaceuticals- ‍expects horizon's cost reallocation initiatives to also result in decrease in no. Of product samples horizon distributes to physicians​.Nuvo Pharmaceuticals Inc - ‍reduction in sample product orders from horizon will have a negative impact on company's future financial results​.  Full Article

Nuvo Pharmaceuticals announces district court decision to uphold U.S. Pennsaid 2% patent
Monday, 15 May 2017 07:30am EDT 

May 15 (Reuters) - Nuvo Pharmaceuticals Inc :Nuvo Pharmaceuticals announces district court decision to uphold U.S. Pennsaid 2% patent.Court upheld validity of Horizon Pharma's U.S. patent covering Pennsaid 2%.Pennsaid 2% has multiple orange book listed patents with terms that extend to 2030.  Full Article

Nuvo Pharmaceuticals announces Q1 EPS C$0.19
Wednesday, 10 May 2017 05:00pm EDT 

May 10 (Reuters) - Nuvo Pharmaceuticals Inc ::Nuvo Pharmaceuticals announces Q1 results.Q1 earnings per share C$0.19 from continuing operations.Q1 revenue C$7.0 million versus C$7.8 million.  Full Article

Nuvo Pharmaceuticals reports Q1 revenue of $7.0 million
Wednesday, 10 May 2017 05:00pm EDT 

May 10 (Reuters) - Nuvo Pharmaceuticals Inc :Nuvo Pharmaceuticals total Q1 revenue for three months ended March 31, 2017 was $7.0 million compared to $7.8 million for three months ended march 31, 2016.Net income from continuing operations was $2.2 million for three months ended march 31, 2017 or $0.19 per share.  Full Article

Nuvo Pharmaceuticals enters into license agreement with Sayre Therapeutics
Tuesday, 28 Mar 2017 07:30am EDT 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals™ enters into pennsaid® 2 pct license agreement with Sayre Therapeutics Pvt Ltd. For India, Sri Lanka, Bangladesh and Nepal . Nuvo Pharmaceuticals Inc - has received an upfront payment and is eligible to receive milestone payments and a double-digit royalty on net sales . Says Nuvo will supply pennsaid 2 pct to sayre on an exclusive basis from its manufacturing facility in varennes, québec . Nuvo Pharmaceuticals Inc - agreement to distribute, market and sell pennsaid 2 pct in India, Sri Lanka, Bangladesh and Nepal ( territory) .Nuvo Pharmaceuticals Inc - expect to complete pennsaid 2 pct out-licensing agreements for other territories throughout 2017 and 2018.  Full Article

Nuvo Pharmaceuticals net income from cont ops $1.7 mln
Wednesday, 1 Mar 2017 05:00pm EST 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals announces 2016 year-end and fourth quarter results . Q4 revenue C$5.6 million versus C$7.7 million . Nuvo Pharmaceuticals - total revenue for three months ended Dec 31, 2016 was $5.6 million compared to $7.7 million for three months ended December 31, 2015 . Nuvo Pharmaceuticals - net income from continuing operations $1.7 million for three months ended Dec 31, 2016 compared to $4.7 million for three months ended Dec 31, 2015 .Nuvo Pharmaceuticals Inc- company expects pennsaid 2% phase 3 trial to be completed and top-line results available in Q2 2017.  Full Article

Nuvo Pharmaceuticals reports Q3 revenue of C$5.5 million
Thursday, 10 Nov 2016 05:30pm EST 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals Inc - net income from continuing operations for Q3 of 2016 was $1.3 million compared to $2.1 million . Nuvo anticipates signing licensing agreements of pennsaid 2pct covering multiple countries beginning in 2017 . Nuvo Pharmaceuticals™ announces 2016 third quarter results .Q3 revenue C$5.5 million.  Full Article

Nuvo Pharmaceuticals appoints Mary-Jane Burkett as new CFO
Thursday, 1 Sep 2016 04:30pm EDT 

Nuvo Pharmaceuticals Inc :Says Mary-Jane Burkett, has been appointed by its board of directors as vice president and chief financial officer of co.  Full Article

Nuvo Pharmaceuticals posts Q2 earnings per share C$0.22
Wednesday, 10 Aug 2016 05:00pm EDT 

Nuvo Pharmaceuticals Inc : Nuvo Pharmaceuticals announces 2016 second quarter results . Q2 revenue C$8.1 million versus C$3.0 million . Q2 earnings per share C$0.22 from continuing operations .Q2 earnings per share C$0.22.  Full Article